Oncoinvent AS, a clinical stage radiopharmaceutical company, announces that its CEO, Jan A. Alfheim will present the company at DNB’s 13th annual Nordic Healthcare Conference 2022 on 15th of December 2022. The presentation will take place from 09:50-10:10 CET in the Market Session Room C2.
Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway
alfheim@oncoinvent.com
+47 464 40 045
Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.
With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.